Abstract 10P
Background
As a result of a significant decrease in smoking prevalence in many countries, the overall incidence of head and neck squamous cell carcinoma (HNSCC) is declining. However, there is a growing recognition of an increased incidence of oral tongue squamous cell carcinoma (OTSCC) in non-smokers and non-drinkers (NSND) for reasons that are yet to be fully understood. OTSCC in NSND and smoker-drinker (SD) individuals have different molecular profiles, as well as distinct immune microenvironments, which may affect their susceptibility to targeted therapies and immunotherapy. The prognostic value of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLS) in localized oral tongue squamous cell carcinoma (OTSCC) remains unclear. This study investigates the prognostic impact of TILs and TLS on recurrence in patients with surgically treated OTSCC in NSND.
Methods
A total of 100 patients with OTSCC underwent complete surgical resection at a single institution with a median follow-up of 35 months (IQR 12-60). TIL presence (minimal, moderate, heavy) and TLS maturation (aggregate, primary follicle, secondary follicle) were graded using brightfield H&E slides according to previously published criteria. The prognostic impact of TILs and TLS on survival was analyzed using multivariable Cox regression, adjusting for prognostic factors (tumor size, depth of invasion, grade, and surgical margin status). Multivariable logistic regression was used to evaluate these factors for associations with early recurrence (≤12 months).
Results
Heavy TIL presence was observed in 41% of cases, and TLS was present in 76%, of which 23% were mature. The presence of mature TLS was associated with reduced odds of early recurrence [OR 0.18, P=0.04], and the presence of heavy TILs was associated with improved overall survival (OS) [HR 0.26, P=0.02]. Tumors categorized as TIL-/TLS- were associated with significantly worse OS [HR 3.5, P=0.02] compared to tumors with heavy TILs or mature TLS.
Conclusions
TILs and mature TLS are independently associated with decreased rate of early recurrence for high-risk localized OTSCC. Further studies should validate these potential low-cost biomarkers.
Editorial acknowledgement
During the preparation of this work the author(s) used Chat GPT in order to checking grammar. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract